文献速递胸部肿瘤

PACIFIC研究更新:Ⅲ期不可切NSCLC放化疗后度伐利尤单抗四年生存

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
PubMed 文献 · J Thorac Oncol · 2021-01-19

PACIFIC研究更新分析显示,在Ⅲ期不可切NSCLC患者放化疗后,度伐利尤单抗巩固治疗对比安慰剂,4年总生存率分别为49.6%与36.3%,4年无进展生存率分别为35.3%与19.5%,中位总生存分别为47.5个月与29.1个月,生存获益持续且安全可控。

要点

  • 度伐利尤单抗组4年OS率为49.6%,安慰剂组为36.3%。
  • 度伐利尤单抗组4年PFS率为35.3%,安慰剂组为19.5%。
  • 中位OS度伐利尤单抗47.5个月,安慰剂29.1个月。

核心结论

  • 放化疗后度伐利尤单抗巩固治疗显示持久的PFS和持续的OS获益。
  • 约49.6%随机接受度伐利尤单抗的患者在4年时仍存活,安慰剂组为36.3%。
  • 35.3%的患者在4年时仍存活且无进展,安慰剂组为19.5%。

研究设计与样本

  • Ⅲ期、安慰剂对照PACIFIC试验,纳入不可切除、Ⅲ期NSCLC且同步放化疗后无进展的患者。
  • 患者按2:1随机接受度伐利尤单抗10 mg/kg静脉注射或安慰剂,每2周一次(≤12个月),按年龄、性别和吸烟史分层。
  • OS和PFS在意向治疗人群中采用分层log-rank检验分析,中位值和4年率用Kaplan-Meier法估计。

主要发现

  • 截至2020年3月20日(中位随访34.2个月,范围0.2-64.9),更新OS的HR=0.71(95%CI: 0.57-0.88),PFS的HR=0.55(95%CI: 0.44-0.67),与主要分析一致。
  • 度伐利尤单抗组中位OS为47.5个月,安慰剂组为29.1个月。
  • 估计4年OS率:度伐利尤单抗组49.6% vs 安慰剂组36.3%;4年PFS率:35.3% vs 19.5%。

关键数值与推荐

  • 主要终点OS的HR=0.68(95%CI: 0.53-0.87;p=0.00251;数据截止2018年3月22日)。
  • 更新分析OS的HR=0.71(95%CI: 0.57-0.88),PFS的HR=0.55(95%CI: 0.44-0.67)。

临床怎么用

  • 对于不可切除、Ⅲ期NSCLC且同步放化疗后无进展的患者,可考虑度伐利尤单抗巩固治疗。
  • 治疗前需评估WHO体能状态评分0或1,不限PD-L1表达状态。
  • 度伐利尤单抗10 mg/kg每2周一次,最长12个月,需监测免疫相关不良事件。

局限性

  • 更新分析为探索性分析。
  • 中位随访34.2个月,4年生存数据仍需更长期随访确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the primary end points of overall survival (OS) (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.53-0.87; p = 0.00251; data cutoff, March 22, 2018) and progression-free survival (PFS) (blinded independent central review; Response Evaluation Criteria in Solid Tumors version 1.1) (HR = 0.52; 95% CI: 0.42-65; p < 0.0001; February 13, 2017) with manageable safety. Here, we report updated analyses of OS and PFS, approximately 4 years after the last patient was randomized. METHODS: Patients with WHO performance status of 0 or 1 (and any tumor programmed death-ligand 1 status) were randomized (2:1) to intravenous durvalumab (10 mg/kg) or placebo, administered every 2 weeks (≤12 months), stratified by age, sex, and smoking history. OS and PFS were analyzed using a stratified log-rank test in the intent-to-treat population. Medians and 4-year OS and PFS rates were estimated by the Kaplan-Meier method. RESULTS: Overall, 709 of 713 randomized patients received durvalumab (n/N=473/476) or placebo (n/N=236/237). As of March 20, 2020 (median follow-up = 34.2 months; range: 0.2-64.9), updated OS (HR = 0.71; 95% CI: 0.57-0.88) and PFS (HR = 0.55; 95% CI: 0.44-0.67) remained consistent with the primary analyses. The median OS for durvalumab was reached (47.5 mo; placebo, 29.1 months). Estimated 4-year OS rates were 49.6% versus 36.3% for durvalumab versus placebo, and 4-year PFS rates were 35.3% versus 19.5% respectively. CONCLUSION: These updated exploratory analyses demonstrate durable PFS and sustained OS benefit with durvalumab after chemoradiotherapy. An estimated 49.6% of patients randomized to durvalumab remain alive at 4 years (placebo, 36.3%), and 35.3% remain alive and progression-free (placebo, 19.5%).

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021. PMID: 33476803. doi:10.1016/j.jtho.2020.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。